Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Basic & Translational Research, Cornea/Ocular Surface, Glaucoma, Retina, Refractive, Business and Innovation, Education and Training

Business in Brief

  • Ocular Therapeutix has announced FDA approval of DEXTENZA for ocular pain following ophthalmic surgery. It is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-surgical ocular pain, offering up to 30 days’ relief with a single administration.
  • Alcon launched their annual Retina Fellows Institute training program in Fort Worth, Texas. Participants took part in a weekend of hands-on surgical training exercises, as part of the company’s commitment to developing the next generation of retinal surgeons. Alcon also announced the acquisition of Tear Film Innovations Inc – the manufacturer of iLux® – signifying their move into the dry eye treatment space.
  • Novartis has announced landmark European approval for one-time gene-therapy Luxturna. It is the first treatment of its kind to improve or restore sight to patients with inherited retinal degenerative diseases caused by mutations in both copies of the RPE65 gene.
  • Notal Vision has been granted breakthrough device designation by the FDA for their home-based OCT platform – a patient-friendly device intended for use between regularly scheduled clinic assessments. The company also announced the appointment of a new CEO – Susan Orr – after the retirement of Quinton Oswald.
  • Results of Glaukos’ recent iStent inject® study have now been released. The prospective, non-randomized trial found a 20 percent IOP reduction in 78 percent of eyes and a mean medication decrease from 68 percent to 0.8 percent. Glaukos is also pursuing FDA approval for additional MIGS surgical and sustained pharmaceutical therapy products. 





Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login as a Guest or via Social Media

About the Author

Phoebe Harkin

I’ve always loved telling stories. So much so, I decided to make a job of it. I finished a Masters in Magazine Journalism and spent three years working as a creative copywriter before itchy feet sent me (back)packing. It took seven months and 13 countries, but I’m now happily settled on The Ophthalmologist, where I’m busy getting stuck into all things eyeballs.

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Related Articles

Subspecialties Basic & Translational Research

Three (Hundred) Blind Mice

| Phoebe Harkin

Subspecialties Glaucoma

A Glimpse Over the Horizon

| Jeffrey O'Callaghan

Subspecialties Cataract

The Crystal Maze

| Eugene Serebryany, Phoebe Harkin

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register